TrialThe oncologist2025

A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations.

Margaret C Wheless et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.